TransMedics Group, Inc. (TMDX) Gross Margin
- Gross margin · 12 months: Value 58.69%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 58.69% | Gross profit / revenue. Period ending 2026-06-30. $392.35M ÷ $668.47M × 100 ≈ 58.69% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 392.35M USD | Gross Profit |
| Revenue | 668.47M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $392.35M | $668.47M | (m) | 58.69% |
| 2026-03-31 | $375.74M | $635.89M | (m) | 59.09% |
| 2025-12-31 | $362.81M | $605.49M | (m) | 59.92% |
| 2025-09-30 | $341.40M | $566.35M | (m) | 60.28% |
| 2025-06-30 | $317.68M | $531.29M | (m) | 59.79% |
| 2025-03-31 | $290.35M | $488.23M | (m) | 59.47% |
| 2024-12-31 | $262.08M | $441.54M | (m) | 59.36% |
| 2024-09-30 | $237.99M | $401.09M | (m) | 59.34% |
| 2024-06-30 | $217.81M | $358.76M | (m) | 60.71% |
| 2024-03-31 | $185.29M | $296.92M | (m) | 62.40% |
| 2023-12-31 | $154.09M | $241.62M | (m) | 63.77% |
| 2023-09-30 | $126.87M | $193.20M | (m) | 65.67% |
| 2023-06-30 | $104.33M | $151.08M | (m) | 69.05% |
| 2023-03-31 | $81.93M | $119.13M | (m) | 68.78% |
| 2022-12-31 | $65.27M | $93.46M | (m) | 69.84% |
| 2022-09-30 | $51.55M | $70.37M | (m) | 73.26% |
| 2022-06-30 | $37.21M | $51.48M | (m) | 72.28% |
| 2022-03-31 | $28.45M | $39.63M | (m) | 71.80% |
| 2021-12-31 | $21.16M | $31.39M | (m) | 67.42% |
| 2021-09-30 | $19.00M | $29.34M | (m) | 64.75% |
| 2021-06-30 | $20.27M | $31.90M | (m) | 63.52% |
| 2021-03-31 | $16.59M | $27.16M | (m) | 61.07% |
| 2020-12-31 | $16.64M | (m) | (m) | (m) |
| 2020-09-30 | $15.55M | $26.60M | (m) | 58.45% |
| 2020-06-30 | $14.73M | $26.50M | (m) | 55.56% |
| 2020-03-31 | $16.15M | $28.80M | (m) | 56.08% |
| 2019-12-28 | $13.86M | $25.84M | (m) | 53.64% |
| 2019-09-28 | (m) | (m) | (m) | (m) |
| 2019-06-29 | (m) | (m) | (m) | (m) |
| 2019-03-30 | (m) | (m) | (m) | (m) |
| 2018-12-29 | $5.73M | $14.66M | (m) | 39.12% |
| 2018-09-29 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |